←
MSmicrocaps1,245 posts
MSmicrocaps avatar

MSmicrocaps

@MSmicrocaps

The microcap index focused on quality+value+momentum at growth inflection points (MSMqi) supported by Cliff Notes & tools: mscliffnotes.substack.com/

◷ Joined November 2023▧ 323 Photos and videos
MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·Oct 29

4 more days left to make your Stock picks for phase 2 of our free 2026 contes due THIS MONDAY BY MIDNIGHT , November 1, 2026. Free to enter, with $5,000 cash prizes. Pick here - investingcontest.com/submit/… The @smallcapdisc conference has now made all their conference presentation replays available. Research to help you with your picks 👇 ▶️ Watch the presentations: smallcapdiscoveries.com/annu… 📊 Explore our AI-assisted analysis of each presentation: investingcontest.com/researc… 💰 Free to enter, with $5,000 in cash prizes up for grabs! Pick 5 starter stocks and 2 bench stocks from participating companies.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

10/ The lesson: one high-margin product on a fixed-cost base can re-rate a forgotten microcap before the numbers fully show it. Funny enough, our original FY2027 GRAFAPEX estimate (US$24.5M) was below the guide and may end up closer to reality.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

9/ Management says US real-world data at ASH (Dec) and the Tandem Meetings (Feb) will drive the next leg of adoption. Even on our more cautious estimates, the stock trades at about 5x to 6x FY2028 EBITDA. If adoption re-accelerates, it’s cheaper still.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

8/ What we’re watching now: The FY2027 guide needs about US$10M a quarter in H2 vs. US$5.7M in the Sep quarter. Monthly purchase data (h/t @fakecashcapital) has been flat near US$2M a month since June, and October was soft. We think the guidance is at risk.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

7/ The re-rating came in steps: - C$2.95 at the note (Jan) - About C$4.04 when the FY2027 guide (US$30M to US$32M of GRAFAPEX) came out (Jun) - About C$4.96 after Q1 (Aug) - A new high of C$5.95 after Q2 (Nov 17)

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

6/ Risks we flagged that faded: - NTAP expiring Sep 2026: renewed to Sep 2027 - Payer pushback: 91% of US lives covered - Debt maturity: refinanced Nov 2025 - Legacy decline: legacy sales actually grew about 9% in H1 FY2027

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

5/ The operating leverage showed up. Sep 2026 quarter: revenue US$29.1M (+18%), adjusted EBITDA US$5.1M (+17%), operating income +77%, and a swing to net income. GRAFAPEX revenue now more than covers its own sales and support costs.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

4/ The launch so far: GRAFAPEX patient demand went from US$2.1M in the Sep 2025 quarter to US$5.6M in the Sep 2026 quarter (+156%). 86 of about 180 US transplant centers have ordered it. The margin beat too: long-term target raised to 85% from 80%.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

3/ Why we liked it: - 7 years of orphan exclusivity - 80%+ gross margin vs. about 60% for the rest of the portfolio - Sales force in place, so most new revenue drops to profit - Peak target of US$100M to US$175M within 5 years About 3x our FY2028 EBITDA estimate at the time

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

2/ Medexus sells about US$100M a year of specialty drugs in North America (hemophilia, arthritis, allergy). In Jan. 2025, the FDA approved GRAFAPEX, the first drug for conditioning before donor stem-cell transplants in AML/MDS. Phase 3: 33% lower risk of death vs. busulfan.

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·6h

1/ On Jan 2, 2026, we published Cliff Note #128 on Medexus ($MDP.TO / $MEDXF) at US$2.14 (about C$2.95). The thesis: a newly approved orphan drug sold through an existing commercial platform. Yesterday it hit C$5.95: a double (+102%). The Cliff Note is now free (link at the end) 🧵

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·10h

For four years, one badly priced contract dragged down this aerospace & defense microcap. It finally got repriced, and Q3, the first quarter with the new prices, comes out Monday (Nov 23). The kicker: gross margin already doubled without it. About 9x our 2027 estimates. Our preview 👇

MSmicrocaps avatar
MSmicrocaps@MSmicrocaps·Nov 18

3 money MultiBagger traits. Companies: •Implementing price increases for the first time in years. •Focusing on higher margin backlog. •Cost escalation clauses in contracts. In these cases, you don’t even need an increase in unit volume to see a sharp rise in sales & EPS.